Manpreet Chadha - Concepedia

Author

Manpreet Chadha

Roswell Park Comprehensive Cancer Center ORCID

Also Known As

M. CHADHA, M. Chadha, M. K. Chadha, Manpreet Chadha, Manpreet K Chadha, Manpreet K. Chadha, Manpreet Kaur Chadha

Publications

780

Citations

H-Index

Concepts

All Affiliations

Roswell Park Comprehensive Cancer Center Translational Genomics Research Institute University at Buffalo, State University of New York

About

Manpreet Chadha is an author at Roswell Park Comprehensive Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	180
2	Pathology	2	2	157
3	Immunology	1	1	75
4	Neurology	1	1	23
5	Pharmacology	1	1	75

Manpreet Chadha

Publications

731

Citations

H-Index

Page 1

	Year	Citations
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher, Annals of Oncology	2016	229
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer Gayle Jameson, Emanuel F. Petricoin, Jasgit C. Sachdev, Breast Cancer Research and Treatment Systems BiologyMetastatic Breast CancerBreast OncologyMulti-omic Molecular ProfilingMedicine	2014	82
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. Johann S. de Bono, Lida A. Mina, Michael Gonzalez, Journal of Clinical Oncology Solid TumorsImmunologyParp ActivityPathologyPharmacotherapy	2013	75
Effect of 25‐hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients Manpreet Chadha, Marwan Fakih, Josephia R. Muindi, The Prostate	2010	53
Vitamin D deficiency and insufficiency among patients with prostate cancer Donald L. Trump, Manpreet Chadha, Annette Y. Sunga, British Journal of Urology	2009	51
Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration‐resistant prostate cancer Manpreet Chadha, Lili Tian, Terry Mashtare, Cancer	2010	47
High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Manpreet Chadha, Jeffrey Lombardo, Terry Mashtare, PubMed	2009	44
Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancer Manpreet Chadha, Umeer Ashraf, David Lawrence, The Prostate	2008	28
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors Elaine T. Lam, Sabine Eckhardt, Wells A. Messersmith, Molecular Cancer Therapeutics	2017	27
Concurrent Oxaliplatin, 5-Fluorouracil, and Radiotherapy in the Treatment of Locally Advanced Esophageal Carcinoma Brigid M. O'Connor, Manpreet Chadha, A. U. Pande, The Cancer Journal	2007	23

Page 1